# 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT03805594** · PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 43 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Stage IV Prostate Cancer
- Stage IVA Prostate Cancer
- Stage IVB Prostate Cancer

## Interventions

- **DRUG:** Lutetium Lu 177-PSMA-617
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03805594
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-10
- **Primary completion:** 2024-01-10
- **Final completion:** 2024-01-10
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03805594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03805594, "177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03805594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*